QuidelOrthoQDEL
QDEL
About: QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.
Employees: 6,600
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
56% more repeat investments, than reductions
Existing positions increased: 111 | Existing positions reduced: 71
33% more first-time investments, than exits
New positions opened: 56 | Existing positions closed: 42
5% more funds holding
Funds holding: 259 [Q3] → 271 (+12) [Q4]
2.95% more ownership
Funds ownership: 106.0% [Q3] → 108.95% (+2.95%) [Q4]
8% more call options, than puts
Call options by funds: $13.9M | Put options by funds: $12.9M
1% more capital invested
Capital invested by funds: $3.25B [Q3] → $3.26B (+$17M) [Q4]
33% less funds holding in top 10
Funds holding in top 10: 9 [Q3] → 6 (-3) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$25
10%
downside
Avg. target
$44
57%
upside
High target
$61
120%
upside
3 analyst ratings
1 positive
33%
1 neutral
33%
1 negative
33%
JP Morgan Casey Woodring 0% 1-year accuracy 0 / 7 met price target | 10%downside $25 | Underweight Maintained | 21 Apr 2025 |
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target | 120%upside $61 | Outperform Maintained | 13 Feb 2025 |
UBS John Sourbeer 0% 1-year accuracy 0 / 3 met price target | 62%upside $45 | Neutral Maintained | 13 Feb 2025 |
Financial journalist opinion
Based on 5 articles about QDEL published over the past 30 days
Positive
Zacks Investment Research
16 hours ago
QuidelOrtho (QDEL) Earnings Expected to Grow: Should You Buy?
QuidelOrtho (QDEL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
6 days ago
Why QuidelOrtho (QDEL) Could Beat Earnings Estimates Again
QuidelOrtho (QDEL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neutral
Business Wire
1 week ago
QuidelOrtho to Report First Quarter 2025 Financial Results
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company”) or (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financial results for its first quarter 2025 ended March 30, 2025, after the market close on Wednesday, May 7, 2025. Following the release of financial results, QuidelOrtho will hold a conference call beginning at.
Positive
Zacks Investment Research
2 weeks ago
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?
QuidelOrtho (QDEL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Neutral
Zacks Investment Research
3 weeks ago
Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now
QDEL continues to witness growth on the back of its strong product portfolio.
Positive
Zacks Investment Research
1 month ago
QuidelOrtho Unveils Results Manager System to Streamline Testing
QDEL introduces the Results Manager System, a powerful tool designed to streamline diagnostic data management, enhance efficiency, and improve patient care.
Neutral
Business Wire
1 month ago
QuidelOrtho® Introduces Results Manager™ System
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”) announces the availability of the QuidelOrtho® Results Manager™ System, an informatics solution designed to address the growing demands of modern laboratories. The Results Manager system provides a seamless, user-friendly experience for community hospitals and point-of-care settings, strengthening informatics capabilities across QuidelOrtho's extensive diagnostics portfolio. The QuidelOrtho Results Manager system.
Neutral
Business Wire
2 months ago
QuidelOrtho to Participate in the 46th Annual Raymond James Institutional Investor Conference
SAN DIEGO--(BUSINESS WIRE)--QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”), a global provider of innovative in-vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will participate in the 46th Annual Raymond James Institutional Investor Conference on Wednesday, March 5, 2025. Members of QuidelOrtho's management team will participate in a presentation at 8:40 a.m. ET / 5:40 a.m. PT.
Positive
The Motley Fool
2 months ago
Why QuidelOrtho Stock Bounced More Than 4% Higher Today
Healthcare in vitro diagnostics company QuidelOrtho (QDEL 4.28%) attracted the right kind of attention from investors after posting its latest quarterly earnings report on Thursday. A rather encouraged market traded the company's shares up by more than 4% in response.
Positive
Zacks Investment Research
2 months ago
QuidelOrtho Stock Gains Following Q4 Earnings Beat, Margins Contract
Despite solid performances by the Labs and Immunohematology units and China and Other regions, QDEL reports soft overall top-line results in fourth-quarter 2024.
Charts implemented using Lightweight Charts™